Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Nanjing Immunophage Biotech Co., Ltd.

Abbvie Inc.

Sichuan University

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Guangzhou Joyo Pharmatech Co., Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Simcere Pharmaceutical Co., Ltd.

Changzhou Yinsheng Pharmaceutical Co., Ltd.

Cstone Pharmaceutical (suzhou) Co., Ltd.

Dongbao Purple Star Biopharmaceutical Co., Ltd

Jianfei Wang

Shuhui Chen

Jian Li

Jie Li

Wenyuan Zhu

Jikui Sun

Peng Li

Wentao Wu

Yuquan Wei

Adrian Hobson

Michael M Friedman

Jing Zhang

Haizhong Tan

Martine Barth

Maria A Argiriadi

Long Zhang

Eric C Breinlinger

Dawn M George

Yang Zhang

Zhifei Fu

Dominique Bonafoux

Didier Thomas

Guangwen Yang

Fabrice Guillier

Qiu Li

Luoting Yu

Hongyu Yang

Xin Tao

Dominique Potin

Yuhai Xing

Guohuang Fan

Kin Chiu Fong

Zhihua Ao

Linlin Dai

Jeremy Edmunds

Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Compound as highly selective ROS1 inhibitor and use thereof

Provided are a class of multi-targeted inhibitors of IRAK4 and BTK, and the use thereof in preparing a drug for treating IRAK4- and BTK-related diseases. The present invention specifically relates to the compounds represented by formula (II), isomers thereof or pharmaceutically acceptable salts thereof.

Oxazole compound as multi-targeted inhibitor of IRAK4 and BTK

The present invention relates to anti-ROR1 antibodies and to methods of using anti-ROR1 antibodies. The anti-ROR1 antibodies described herein are useful for the diagnosis and treatment of diseases, such as various cancers, associated with aberrant expression of ROR1.

Anti-ROR1 antibodies and preparation method and uses thereof

Provided are a crystal of a compound of formula (I), salt thereof, a crystal of the salt thereof, and a preparation method for the crystal. Also comprised are applications of the compound and the crystal in preparation of drugs for treating IRAK4-related diseases.

IRAK4 inhibitor crystal and preparation method therefor

The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.

Compounds and their uses as MIF inhibitors

A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases. 

Pyrazolopyrimidine derivative and use thereof

Disclosed in the present invention are an IRAK4 inhibitor, and an application thereof in preparation of a drug for treating IRAK4-related diseases. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof. 

Isothiazolo[5,4-D]pyrimidine compound as IRAK4 inhibitor

Disclosed are a crystal of a 4-(naphthalene-1-yl)-4H-1,2,4-triazole compound (1) and a preparation method therefor, also comprised are applications of the crystal in preparing a medicament for treating an abnormal uric acid level-related disease. 

Crystal and salt of 4-(naphthalen-1-yl)-4H-1,2,4-triazole compound and preparation method therefor

Disclosed are a crystal form of a URAT1 inhibitor, and a preparation method therefor. 

Crystal form of URAT1 inhibitor, and preparation method therefor

The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and application of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. 

Thiophene, manufacturing method thereof, and pharmaceutical application of same

A halogenated compound, an axially chiral isomer thereof, and an application thereof in preparing drugs for disorders closely related to aberrant levels of uric acid.

Halogenated compound and axially chiral isomer thereof

Disclosed are two axially chiral isomers and pharmaceutically available salts thereof, preparation method therefor, and pharmaceutical use of the two axially chiral isomers or pharmaceutical compositions thereof.

Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof

Provided is a benzofuran analog having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analog. The benzofuran analog has anti-hepatitis C virus activity.

Benzofuran analogue as NS4B inhibitor

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof

Growing community of inventors

Shanghai, China

Jianfei Wang